| [1] |
Chen J, Zhu Q, Yu L, et al. Stroke risk factors of stroke patients in China: a nationwide community-based cross-sectional study[J]. Int J Environ Res Public Health, 2022, 19(8): 4807. DOI: 10.3390/ijerph19084807.
|
| [2] |
|
| [3] |
|
| [4] |
Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial[J]. Lancet, 2014, 383(9914): 333-341. DOI: 10.1016/S0140-6736(13)62038-3.
|
| [5] |
Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial[J]. JAMA, 2015, 313(12): 1240-1248. DOI: 10.1001/jama.2015.1693.
|
| [6] |
Gao P, Wang T, Wang D, et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the CASSISS randomized clinical trial[J]. JAMA, 2022, 328(6): 534-542. DOI: 10.1001/jama.2022.12000.
|
| [7] |
Yang L, Du H, Zhang D, et al. Complications and long-term in-stent restenosis of endovascular treatment of severe symptomatic intracranial atherosclerotic stenosis and relevant risk factors[J]. Medicine (Baltimore), 2023, 102(38): e34697. DOI: 10.1097/MD.0000000000034697.
|
| [8] |
Wang N, Lu Y, Feng L, et al. Identifying risk factors for in-stent restenosis in symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis[J]. Front Neurol, 2023, 14: 1170110. DOI: 10.3389/fneur.2023.1170110.
|
| [9] |
Peng G, Zhang Y, Miao Z. Incidence and risk factors of in-stent restenosis for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis[J]. AJNR Am J Neuroradiol, 2020, 41(8): 1447-1452. DOI: 10.3174/ajnr.A6689.
|
| [10] |
Yoon NK, Awad AW, Kalani MY, et al. Stent technology in ischemic stroke[J]. Neurosurg Focus, 2017, 42(4): E11. DOI: 10.3171/2017.1.
|
| [11] |
Derdeyn CP, Fiorella D, Lynn MJ, et al. Nonprocedural symptomatic infarction and in-stent restenosis after intracranial angioplasty and stenting in the SAMMPRIS trial (stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis)[J]. Stroke, 2017, 48(6): 1501-1506. DOI: 10.1161/STROKEAHA.116.014537.
|
| [12] |
Wang N, Lu Y, Feng L, et al. Identifying risk factors for in-stent restenosis in symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis[J]. Front Neurol, 2023, 14: 1170110. DOI: 10.3389/fneur.2023.1170110.
|
| [13] |
Ronchey S, Praquin B, Orrico M, et al. Outcomes of 1000 carotid wallstent implantations: single-center experience[J]. J Endovasc Ther, 2016, 23(2): 267-274. DOI: 10.1177/1526602815626558.
|
| [14] |
Chen W, Huang F, Li M, et al. Incidence and predictors of the in-stent restenosis after vertebral artery ostium stenting[J]. J Stroke Cerebrovasc Dis, 27(11): 3030-3035. DOI: 10.1016/j.jstrokecerebrovasdis.2018.06.031.
|
| [15] |
Zheng D, Mingyue Z, Wei S, et al. The incidence and risk factors of in-stent restenosis for vertebrobasilar artery stenting[J]. World Neurosurg, 2018, 110: e937-e941. DOI: 10.1016/j.wneu.2017.11.112.
|
| [16] |
Alexander MJ, Zauner A, Gupta R, et al. The WOVEN trial: wingspan one-year vascular events and neurologic outcomes[J]. J Neurointerv Surg, 2021, 13(4): 307-310. DOI: 10.1136/neurintsurg-2020-016208.
|
| [17] |
Yang K, Fang S, Zhang X, et al. In-stent restenosis after vertebral artery origin stenosis stenting: a nomogram for risk assessment[J]. J Neurointerv Surg, 2023, 15(e1): e41-e45. DOI: 10.1136/neurintsurg-2022-019091.
|
| [18] |
|
| [19] |
Takao N, Hagiwara Y, Shimizu T, et al. Preprocedural carotid plaque echolucency as a predictor of in-stent intimal restenosis after carotid artery stenting[J]. J Stroke Cerebrovasc Dis, 2020, 29(12): 105339. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105339.
|
| [20] |
Cyr AR, Huckaby LV, Shiva SS, et al. Nitric oxide and endothelial dysfunction[J]. Crit Care Clin, 2020, 36(2): 307-321. DOI: 10.1016/j.ccc.2019.12.009.
|
| [21] |
Tsuji Y, Koide M, Katsura K, et al. In-stent restenosis with "inflammatory" neointima following everolimus-eluting stent implantation[J]. Int Heart J, 2018, 59(5): 1142-1145. DOI: 10.1536/ihj.17-602.
|
| [22] |
Yu Y, Yan L, Lou Y, et al. Multiple predictors of in-stent restenosis after stent implantation in symptomatic intracranial atherosclerotic stenosis[J]. J Neurosurg, 2022, 136(6): 1716-1725. DOI: 10.3171/2021.6.Jns211201.
|
| [23] |
Shen J, Song JB, Fan J, et al. Distribution and dynamic changes in matrix metalloproteinase (MMP)-2, MMP-9, and collagen in an in stent restenosis process[J]. Eur J Vasc Endovasc Surg, 2021, 61(4): 648-655. DOI: 10.1016/j.ejvs.2020.11.035.
|
| [24] |
Yan LL, Wei XH, Shi QP, et al. Cardiotonic pills® protects from myocardial fibrosis caused by in stent restenosis in miniature pigs[J]. Phytomedicine, 2022, 106: 154405. DOI: 10.1016/j.phymed.2022.154405.
|
| [25] |
Liu JP, Wang YZ, Li YK, et al. Matrix metalloproteinase 9 level as an indicator for restenosis following cervical and intracranial angioplasty and stenting[J]. Neural Regen Res, 2015, 10(4): 631-635. DOI: 10.4103/1673-5374.155439.
|
| [26] |
Gutierrez-Carretero E, Mayoral-González I, Jesús Morón F, et al. miR-30b-5p downregulation as a predictive biomarker of coronary in-stent restenosis[J]. Biomedicines, 2021, 9(4): 354. DOI: 10.3390/biomedicines9040354.
|
| [27] |
Haidegger M, Kneihsl M, Niederkorn K, et al. Blood biomarkers of progressive atherosclerosis and restenosis after stenting of symptomatic intracranial artery stenosis[J]. Sci Rep, 2021, 11(1): 15599. DOI: 10.1038/s41598-021-95135-y.
|
| [28] |
Tian B, Zhu C, Tian X, et al. Baseline vessel wall magnetic resonance imaging characteristics associated with in-stent restenosis for intracranial atherosclerotic stenosis[J]. J Neurointerv Surg, 2023, 15(3): 288-291. DOI: 10.1136/neurintsurg-2021-018473.
|
| [29] |
Yang WJ, Fisher M, Zheng L, et al. Histological characteristics of intracranial atherosclerosis in a Chinese population: a postmortem study[J]. Front Neurol, 2017, 8: 488. DOI: 10.3389/fneur.2017.00488.
|
| [30] |
de Donato G, Pasqui E, Alba G, et al. Clinical considerations and recommendations for OCT-guided carotid artery stenting[J]. Expert Rev Cardiovasc Ther, 2020, 18(4): 219-229. DOI: 10.1080/14779072.2020.1756777.
|
| [31] |
Feng Y, Dmytriw AA, Yang B, et al. Neovascularization in human intracranial atherosclerotic in-stent restenosis[J]. Diagnostics (Basel), 2021, 11(2): 322. DOI: 10.3390/diagnostics11020322.
|
| [32] |
Liu H, Liu Y, Ip BYM, et al. Effects of stent shape on focal hemodynamics in intracranial atherosclerotic stenosis: a simulation study with computational fluid dynamics modeling[J]. Front Neurol, 2022, 13: 1067566. DOI: 10.3389/fneur.2022.1067566.
|
| [33] |
Texakalidis P, Tzoumas A, Giannopoulos S, et al. Risk factors for restenosis after carotid revascularization: a meta-analysis of hazard ratios[J]. World Neurosurg, 2019, 125: 414-424. DOI: 10.1016/j.wneu.2019.02.065.
|
| [34] |
Vanags LZ, Wong NKP, Nicholls SJ, et al. High-density lipoproteins and apolipoprotein A-I improve stent biocompatibility[J]. Arterioscler Thromb Vasc Biol, 2018, 38(8): 1691-1701. DOI: 10.1161/atvbaha.118.310788.
|
| [35] |
Turan TN, Nizam A, Lynn MJ, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial[J]. Neurology, 2017, 88(4): 379-385. DOI: 10.1212/wnl.0000000000003534.
|
| [36] |
Huang X, Wang X, Zou Y, et al. Impact of cigarette smoking and smoking cessation on stent changes as determined by optical coherence tomography after sirolimus stent implantation[J]. Am J Cardiol, 2017, 120(8): 1279-1284. DOI: 10.1016/j.amjcard.2017.07.011.
|
| [37] |
Anjorin AC, Marcaccio CL, Rastogi V, et al. Statin therapy is associated with improved perioperative outcomes and long-term mortality following carotid revascularization in the vascular quality initiative[J]. J Vasc Surg, 2023, 77(1): 158-169.e8. DOI: 10.1016/j.jvs.2022.08.019.
|
| [38] |
Kang Z, Cao Y, Li L, et al. The association between apolipoprotein E gene polymorphism and in-stent restenosis after extracranial and intracranial artery stenting[J]. J Stroke Cerebrovasc Dis, 2021, 30(1): 105424. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105424.
|
| [39] |
Zhang M, Wang J, Zhang Y, et al. Impacts of CYP2C19 polymorphism and clopidogrel dosing on in-stent restenosis: a retrospective cohort study in Chinese patients[J]. Drug Des Devel Ther, 2020, 14: 669-676. DOI: 10.2147/dddt.S242167.
|
| [40] |
Qiao H, Chang CH, Wang AY, et al. Safety and efficacy of drug coated balloon angioplasty for intracranial atherosclerotic disease[J]. J Neurointerv Surg, 2023, 15(e2): e172-e177. DOI: 10.1136/jnis-2022-019122.
|
| [41] |
Jia B, Zhang X, Ma N, et al. Comparison of drug-eluting stent with bare-metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis: a randomized clinical trial[J]. JAMA Neurol, 2022, 79(2): 176-184. DOI: 10.1001/jamaneurol.2021.4804.
|
| [42] |
Ma X, Jiang C, Li Y, et al. Inhibition effect of tacrolimus and platelet-derived growth factor-BB on restenosis after vascular intimal injury[J]. Biomed Pharmacother, 2017, 93: 180-189. DOI: 10.1016/j.biopha.2017.06.027.
|
| [43] |
Guo X, Ma N, Gao F, et al. Long-term risk factors for intracranial in-stent restenosis from a multicenter trial of stenting for symptomatic intracranial artery stenosis registry in China[J]. Front Neurol, 2020, 11: 601199. DOI: 10.3389/fneur.2020.601199.
|
| [44] |
Zhang K, Li TX, Wang ZL, et al. Factors affecting in-stent restenosis after angioplasty with the enterprise stent for intracranial atherosclerotic diseases[J]. Sci Rep, 2021, 11(1): 10479. DOI: 10.1038/s41598-021-89670-x.
|
| [45] |
Park SC, Cho SH, Kim MK, et al. Long-term outcome of angioplasty using a wingspan stent, post-stent balloon dilation and aggressive restenosis management for intracranial arterial stenosis[J]. Clin Neuroradiol, 2020, 30(1): 159-169. DOI: 10.1007/s00062-019-00793-1.
|
| [46] |
|
| [47] |
Ye G, Yin X, Yang X, et al. Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease: a systematic review and meta-analysis[J]. J Clin Neurosci, 2019, 59: 112-118. DOI: 10.1016/j.jocn.2018.10.118.
|
| [48] |
Guo Z, Liu C, Huang K, et al. Meta-analysis of redo stenting versus endarterectomy for in-stent stenosis after carotid artery stenting[J]. J Vasc Surg, 2021, 73(4): 1282-1289. DOI: 10.1016/j.jvs.2020.07.102.
|
| [49] |
|
| [50] |
Yazdani SK, Lei B, Cawthon CV, et al. Local intraluminal delivery of a smooth muscle-targeted RNA ligand inhibits neointima growth in a porcine model of peripheral vascular disease[J]. Mol Ther Nucleic Acids, 2022, 29: 577-583. DOI: 10.1016/j.omtn.2022.08.007.
|
| [51] |
Zhu J, Liu B, Wang Z, et al. Exosomes from nicotine-stimulated macrophages accelerate atherosclerosis through miR-21-3p/PTEN-mediated VSMC migration and proliferation[J]. Theranostics, 2019, 9(23): 6901-6919. DOI: 10.7150/thno.37357.
|